[Scientific, transparent and applicable rankings of Chinese guidelines and consensus published in the medical journals between 2023 and 2024].

Abstract

To further promote continuous quality improvement of clinical practice guidelines (CPGs) and expert consensuses (ECs) in China, the Scientific, Transparent, and Applicable Rankings (STAR) Working Group conducted its 2023-2024 biennial appraisal based on its previous work. In this round, 40 specialty committees and over 1 000 experts participated, and large language model technologies were integrated to comprehensively evaluate guidelines and consensuses led by Chinese scholars and published in journals between 2023 and 2024. A total of 305 guidelines and 1 153 consensuses were included for 2023, compared to 424 guidelines and 1 391 consensuses for 2024. The average scores for guidelines and consensuses increased from 41.0 and 28.8 in 2023 to 49.2 and 33.0 in 2024, respectively, indicating a significant upward trend compared with previous years. Among the evaluation domains, "Recommendations" achieved the highest scoring rate, whereas "Protocols" and "Funding and Conflict of Interest Disclosures" recorded the lowest. In terms of publication volume, Oncology, Traditional Chinese Medicine, and Pediatrics were the top three specialties. Overall, medical guidelines and consensus documents in China are at a critical stage of transitioning from"quantity-driven"expansion to"high-quality development."In the future, guideline developers, academic journals, and the STAR Working Group should establish long-term collaborative mechanisms to jointly promote the dynamic and intelligent evolution of the ranking system. 为持续促进我国指南和共识质量的整体提升，指南科学性（Scientific）、透明性（Transparent）和适用性（Applicable）评级（Rankings）（简称“STAR”）工作组在既有基础上完成了2023—2024年双年度指南和共识评级工作。本次工作由40个专科委员会、1 000余名专家共同参与，并结合大语言模型技术，对2023—2024年由中国学者牵头在期刊发表的指南与共识进行综合评价。结果显示，2023与2024年分别纳入指南305部与424部，共识1 153部与1 391部。指南与共识平均得分从2023年的41.0分、28.8分提升至2024年的49.2分、33.0分。各评价领域中，“推荐意见”得分率最高，“计划书”与“资助作用说明”得分率最低。发表数量方面，肿瘤学、中医药学与儿科学位居前三。总体来看，我国医学指南和共识正处于由“数量驱动”向“高质量发展”转型的关键阶段。未来指南和共识制订者、期刊和STAR工作组应建立长效合作机制，共同推动评级的动态化和智能化。.